The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 10, 2005, Pages 987-991

  Ozeren, Mehmet ^a   Karahan, S Caner ^a   Ozgur, Mustafa ^a   Eminagaogu, Selcuk ^a   Unsal, Mesut ^a   Baytan, Sukrucan ^a   Bozkaya, Hasan ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Fibrinolysis; PAI 1; Procarboxypeptidase U; Raloxifene; TAFI; tPA

Indexed keywords

CALCIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; RALOXIFENE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT COURSE THERAPY; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTIGENS; CALCIUM, DIETARY; CARBOXYPEPTIDASE U; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 25844522699     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00817.x     Document Type: Article

References (24)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
2. Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837-44.
3. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
4. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993-3000.
5. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11: 183-93.
6. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
7. Hendriks DF, Scharpe SS, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
8. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
9. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF. Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 2000; 292: 25-40.
10. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
11. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
12. Libourel EJ, Bank I, Meinardi JR, Balje-Volkers CP, Hamulyak K, Middeldorp S et al. Co- segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87: 1068-73.
13. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 2156-61.
14. Post MS, Hendriks DF, Van Der Mooren MJ, Van Baal WM, Leurs JR, Emeis JJ et al. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J Intern Med 2002; 251: 245-51.
15. Vogelvang TE, Leurs JR, van der Mooren MJ, Mijatovic V, Hendriks DF, Neele S et al. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women. Menopause 2004; 11: 110-5.
16. Raloxifene hydrochloride. PDR® Electronic Library, Version 6.1.301a-2004.1.1.
17. Samuelsson E, Hagg S. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand 2004; 83: 674-81.
18. Azevedo GD, Franco RF, Baggio MS, Maranhao TM, Ferriani RA, Silva de Sa MF. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women. Climacteric 2003; 6: 140-5.
19. Stromqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 12-7.
20. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
21. Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.
22. Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003; 1: 1208-14.
23. Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25: 252-9.
24. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 2002; 13: 373-81.